Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Aytu Biopharma Inc AYTU

Healthcare
Aytu BioPharma, Inc. is a pharmaceutical company commercializing a portfolio of commercial prescription therapeutics and consumer health products. The Company’s Rx segment consists of prescription pharmaceutical products and the Consumer Health segment consists of various consumer healthcare products (the Consumer Health Portfolio). The Company’s prescription products include Adzenys XR-ODT (amphetamine) extended-release orally disintegrating tablets and Cotempla XR-ODT (methylphenidate) extended-release orally disintegrating tablets for the treatment of attention deficit hyperactivity disorder (ADHD); Karbinal ER (carbinoxamine maleate), an extended-release antihistamine suspension indicated to treat numerous allergic conditions; and Poly-Vi-Flor and Tri-Vi-Flor, two complementary fluoride-based prescription vitamin product lines available in various formulations for infants and children with fluoride deficiency. Its Consumer Health Segment addresses a range of common conditions.


NDAQ:AYTU - Post by User

Aytu Biopharma Inc
Bullboard Posts
User Avatar Image
(0)
•••
Post by mrdoobeeon Mar 07, 2019 2:03pm
134 Views
Post# 29456749

AYTU UP 44% ON ZOLPIMIST LICENSING DEAL

AYTU UP 44% ON ZOLPIMIST LICENSING DEALhttps://seekingalpha.com/news/3440319-aytu-bio-44-percent-zolpimist-licensing-deal

Thinly traded nano cap Aytu BioScience (AYTU +43.6%) is up on a whopping 44x surge in volume in response to its in-licensing partnership with SUDA Pharmaceuticals for the distribution of sleep aid ZolpiMist (zolpidem tartrate oral spray) outside of the U.S. and Canada (Sanofi markets the tablet formulation under the Ambien brand). The companies assumed the license from Magna Pharmaceuticals.

SUDA will lead development and sublicensing activities. Agreements with "multinational pharmaceutical companies" are already in place in China, Chile, Brazil and throughout Southeast Asia.

SUDA will pay Aytu a portion of each upfront and milestone payment received from sublicensees in addition to ongoing royalties from net sales.


Bullboard Posts
Dealroom for high-potential pre-IPO opportunities